首页> 外文期刊>The journal of clinical hypertension. >Should patients with chronic kidney disease have an ambulatory BP monitor for accurate renal and cardiovascular risk assessment?
【24h】

Should patients with chronic kidney disease have an ambulatory BP monitor for accurate renal and cardiovascular risk assessment?

机译:慢性肾脏病患者是否应配备动态血压监测仪以进行准确的肾脏和心血管风险评估?

获取原文
获取原文并翻译 | 示例
           

摘要

Approximately 19 million adults in the United States have chronic kidney disease (CKD) and the prevalence of CKD continues to increase. Patients with CKD have an increased risk of cardiovascular (CV) disease and most CKD patients die before reaching the need for dialysis. There is constant debate about optimal BP goals for the nondialysis CKD population with ongoing studies in this area (Systolic Blood Pressure Intervention Trial [SPRINT]). The current guidelines advocate a goal blood pressure (BP) of <130/80 mm Hg with even tighter BP control in patients with significant proteinuria. These guidelines are based on office BP measurements. A recently published study questions the validity of these office BP guidelines in the nondialysis CKD population.Minutolo and colleagues3 evaluated the prognostic role of ambulatory BP monitoring (ABPM) in patients with nondialysis CKD stages 2 to 4. This was a prospective cohort study of 436 patients at . Italian nephrology units seen between January 2003 until December 2005. Patients were followed for a median of 4.2 years.
机译:在美国,大约有1900万成年人患有慢性肾脏病(CKD),并且CKD的患病率持续上升。 CKD患者罹患心血管(CV)疾病的风险增加,并且大多数CKD患者在未达到透析需求之前就死亡。关于非透析CKD人群的最佳BP目标一直存在争论,该领域正在进行研究(收缩压干预试验[SPRINT])。当前的指南提倡将目标血压(BP)降至<130/80 mm Hg,并且对患有严重蛋白尿的患者进行更严格的BP控制。这些准则基于办公室的BP测量。最近发表的一项研究对这些办公室BP指南在非透析CKD人群中的有效性提出了质疑。Minutolo及其同事3评估了非透析CKD 2至4期患者动态BP监测(ABPM)的预后作用。这是一项前瞻性队列研究,涉及436的患者。从2003年1月至2005年12月在意大利的肾脏病科就诊。对患者的平均随访时间为4.2年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号